Canaccord Genuity initiated coverage on Quantum-Si with a new price target
$QSI
Industrial Machinery/Components
Industrials
Canaccord Genuity initiated coverage of Quantum-Si with a rating of Buy and set a new price target of $13.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/8/2023 | $3.00 | Buy | H.C. Wainwright |
| 9/25/2023 | $3.50 → $2.00 | Buy → Hold | Canaccord Genuity |
| 10/20/2021 | $13.00 | Buy | Canaccord Genuity |
Sales Pipeline is Accelerating and New Kits Remain on Track for Q4 Launch Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced financial results for the third quarter ended September 30, 2024. Press Release Highlights Reported revenue of $787,000 for the third quarter of 2024 Announced that Liberate Bio has integrated Platinum® Next-Generation Sequencing into their platform for developing novel gene therapies with improved targeting capabilities Announced appointments of industry veteran Todd Bennett as Chief Commercial Officer ("CCO"), John Vieceli, Ph.D. as Chief Product Officer and Lindsay Thompson as C
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing CompanyTM, today announced that it will report financial results for the third quarter of 2024 on Tuesday, November 12, 2024. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:00 AM ET. Individuals interested in listening to the conference call may do so by joining the live webcast on the Investors section of the Quantum-Si website under Events and Presentations. Alternatively, individuals can register here to receive a dial-in number and personalized PIN to participate in the call. An archived webcast of the event
Announces Release of Version 3 Sequencing Kit Announces Two Additional Kit Launches Expected by End of 2024 Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced financial results for the second quarter ended June 30, 2024. Press Release Highlights Reported revenue of $622,000 in the second quarter of 2024 Completed the first quarter of full commercial launch of the Platinum® instrument in Q2 2024 Announces the launch of the version 3 sequencing kit Announced appointment of Chuck Kummeth as independent Chairman of the Board of Directors Expect to l
H.C. Wainwright initiated coverage of Quantum-Si with a rating of Buy and set a new price target of $3.00
Canaccord Genuity downgraded Quantum-Si from Buy to Hold and set a new price target of $2.00 from $3.50 previously
Canaccord Genuity initiated coverage of Quantum-Si with a rating of Buy and set a new price target of $13.00
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, and IDEX Health & Science, LLC., today announced they will partner on the development and manufacturing of the optics module for Quantum-Si's novel proteomics platform, Proteus™. IDEX Health & Science, LLC is the global leader in life science optics, fluidics and microfluidics, offering a three-fold advantage to customers by bringing optofluidic paths to life with strategic partnerships, breakthrough solutions, and proven expertise. Through the Melles Griot and Semrock product lines, IDEX Health & Science offers the broadest and most complete solution to support customer optical n
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, announces its participation in the upcoming Festival of Genomics UK, taking place on January 29–30, 2025, at ExCeL London. As part of the event, Richard Broadhead, Ph.D., will deliver a presentation highlighting the latest innovations in Next-Generation Protein Sequencing™ and its transformative impact on proteomics and multiomics research. Dr. Broadhead's talk, titled "Advancing Multiomics with Next-Generation Protein Sequencing™: High-Resolution Protein and Proteoform Characterization with an Accessible Workflow," will explore how Quantum-Si's groundbreaking Platinum® Pro platfo
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced that the Compensation Committee of Quantum-Si's Board of Directors has granted 44,893 restricted stock units ("RSUs") to new employees under the Company's previously adopted Quantum-Si Incorporated 2023 Inducement Equity Incentive Plan, as amended (the "2023 Inducement Plan"). The RSUs were granted as an inducement material to the new employees becoming an employee of Quantum-Si in accordance with Nasdaq Listing Rule 5635(c)(4). The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Quantum-Si
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced the appointment of Charles ("Chuck") Kummeth to the role of independent Chairman of the Board, effective May 27, 2024. Mr. Kummeth has over 35 years of leadership experience in Life Sciences most recently as President and CEO of Bio-Techne. During Mr. Kummeth's tenure at Bio-Techne, he oversaw tremendous growth across all aspects of the business including annual revenue growth from $300M to over $1.1B, growth in the employee base from 800 to over 3,000, and the successful execution of 19 acquisitions, all while maintaining a 35% or better EBITDA level. Under Mr. Ku
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing CompanyTM, today announced the appointment of Paula Dowdy, a senior executive with more than 35 years of experience across life sciences, enterprise software, and technology industries, to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240321183506/en/Paula Dowdy (Photo: Business Wire) Ms. Dowdy currently serves on the Board of Directors for SPT Labtech, a world leading lab automation tools company based in the UK and is an advisor at EQT Life Sciences, one of Europe's leading investors targeting innovative
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced that it has entered into an agreement with a new distributor who will make the company's protein sequencing instrument, Platinum® available for the first time in Japan. TOMY Digital Biology Co., Ltd., a renowned importer and distributor with a rich history dating back to the 1950s, will distribute Quantum-Si's next-generation protein sequencer™ and associated consumables throughout Japan. "Working with Quantum-Si marks a pivotal moment for TOMY Digital Biology, aligning with our commitment to advancing life sciences. We're poised to empower Japanese researchers wit
4 - Quantum-Si Inc (0001816431) (Issuer)
4 - Quantum-Si Inc (0001816431) (Issuer)
4 - Quantum-Si Inc (0001816431) (Issuer)
SCHEDULE 13G/A - Quantum-Si Inc (0001816431) (Subject)
8-K - Quantum-Si Inc (0001816431) (Filer)
424B5 - Quantum-Si Inc (0001816431) (Filer)
4 - Quantum-Si Inc (0001816431) (Issuer)
4 - Quantum-Si Inc (0001816431) (Issuer)
4 - Quantum-Si Inc (0001816431) (Issuer)
SC 13D/A - Quantum-Si Inc (0001816431) (Subject)
SC 13G/A - Quantum-Si Inc (0001816431) (Subject)
SC 13G - Quantum-Si Inc (0001816431) (Subject)